)
)
)
Perseo pharma AG
March 02, 2026
Ballroom II C
Type: Company Presentation
Focus Area:
Metabolic Diseases
Perseo Pharma is a biopharmaceutical company pioneering innovative metabolic therapies. The company has raised USD 12 million from private investors, including a U.S. patient advocacy organization and a corporate fund. We are currently raising our USD 9M Series A, for which we have signed a Term Sheet with a US investor. Perseo's proprietary platform technology enables the development of highly effective gut-restricted treatments for a range of metabolic disorders. The company is targeting conditions like Exocrine Pancreatic Insufficiency (EPI) and a family of rare diseases made of Intoxication-Type Inborn Errors of Metabolism. PER301, Perseo's lead compound for EPI (well established $1.5bn market in the US alone), is being developed in partnership with Nestlé Health Science. A significant commercial milestone for this collaboration was reached at the end of 2025.
Year Founded:
2019
Lead Product in Development:
PER301, Best-in-Class Pancreatic Enzyme Replacement Therapy
Speakers
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
